



Positive disruption is our mission:

Mazen Animal Health is a new company focused on developing, delivering and commercializing novel biological vaccines and therapeutics that disrupt the status quo and address complex or unsolved challenges in animal health and protein production. Our first disruptive solution is a reinvention of vaccines with a novel technology platform that will shift the paradigm in disease prevention.

Leveraging developed platform technology from Applied Biotechnology Institute, Mazen will use its exclusive license to develop & commercialize unique oral vaccines with an efficient, cost-effective platform technology appropriate for production, companion & wildlife animals that simplifies dosing management, eliminates cold chain systems, provides a solution for disease prevention, and reduces antibiotic use.

Protection in animals from pathogens after oral administration of vaccines using this technology has already been demonstrated. Mazen has identified our first two commercial product candidates and initial animal data is anticipated in Q2-18, at which time the company will be raising a Series A round to fund the development and commercialization of the first candidates while building a robust pipeline of products.

Technology & IP:

The platform technology involves expression of antigens in maize grain. These safe subunit antigens provide both mucosal and systemic immunity enabling the potential to be more efficacious than current injectable vaccines. Maize grain containing antigen is ground into meal and formulated into the appropriate dosage form. In addition to new IP being generated and owned by Mazen, Mazen has a license, exclusive in animal health, to a portfolio of issued and pending patents.

Market Opportunity:

Global animal vaccine market was \$5.4B in 2014 with double-digit growth in traditional vaccination. Mazen's vaccines offer an opportunity to expand the existing market by increasing the vaccination rates due to easier-to-use, cost-effective, more efficacious vaccines.

Based upon current product development plans and the financial projections, Mazen will have \$300M in revenue in 7 years. The first product will launch in 2020 and in 2025, will have 10 products on the market with a rich pipeline in development.

Financing History & Plans:

Mazen has raised \$670,000 in a convertible debt round which has allowed us to achieve our milestones: expression of antigen, positive meeting with USDA-CVB, affirmative feedback from market research, a co-authored SBIR grant application with a major AH company, and planned animal studies in Q2-18.

Mazen plans to raise a Series A round upon animal data showing efficacy in vaccines for PEDV in pigs and Valley Fever targeted for companion animals. The funding will take us to product commercialization with two lead products 2020/2021 and will allow us to grow a robust pipeline of products. In this position, Mazen would be a candidate for IPO to fund broader commercialization efforts or an M&A with a major animal health company looking to acquire revenue stream and pipeline.

Leadership Team:

Mazen is led by the founders supported by a group of advisors with expertise in animal health, regulatory, manufacturing, marketing and growing businesses. Team expansion is planned in Q2-18 with additions of CFO, Marketing, R&D.

Founders: Jennifer Filbey, CEO; John Howard, CoB; Celine Hayden, R&D; Vicki Morgan, BD

Board: Terry Speizer, Ronan Molloy, Kelly Lechtenberg, Jennifer Filbey, John Howard

Advisors/Extended Team: Tom Overbay, Expedite; Dick Hesse, K-State; Stephens & Associates